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Summary Chronic obstructive pulmonary disease (COPD) is a serious and mounting
global public health problem. Although its pathogenesis is incompletely understood,
chronic inflammation plays an important part and so new therapies with a novel anti-
inflammatory mechanism of action may be of benefit in the treatment of COPD.
Cilomilast and roflumilast are potent and selective phosphodiesterase (PDE)4
inhibitors, with an improved therapeutic index compared with the weak, non-
selective PDE inhibitor, theophylline. Unlike theophylline, which is limited by poor
efficacy and an unfavourable safety and tolerability profile, the selective PDE4
inhibitors are generally well tolerated, with demonstrated efficacy in improving lung
function, decreasing the rate of exacerbations and improving quality of life, with
proven anti-inflammatory effects in patients with COPD. Theophylline is a difficult
drug to use clinically, requiring careful titration and routine plasma monitoring due
to the risk of toxic side effects, such as cardiovascular and central nervous system
adverse events, with dose adjustments required in many patients, including
smokers, the elderly and some patients on concomitant medications. In contrast,
the selective PDE4 inhibitors are convenient medications for both patient and
physician alike. Hence these agents represent a therapeutic advance in the
treatment of COPD, due to their novel mechanism of action and potent anti-
inflammatory effects, coupled with a good safety and tolerability profile.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Globally, chronic obstructive pulmonary disease
(COPD) is a serious and mounting public health
problem. The prevalence of COPD, currently
estimated at 600 million worldwide by the World
Health Organization (WHO), may be underdiag-
nosed by as much as 50%.1–3 COPD was the sixth
leading cause of death in 1990 according to the
Global Burden of Disease (GBD) Study and is
predicted to rise to third place by 2020.4 Moreover,
the GBD Study predicts that COPD will become the
fifth highest ranking disease worldwide by 2020 in
terms of disability-adjusted life years (DALYs),
further reflecting the extent of the burden imposed
by the condition.5
According to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD), a collaborative
project of the US National Heart, Lung and Blood
Institute and the World Health Organization, COPD
fails to receive adequate attention from the
healthcare community and government policy
makers and, historically, information concerning
its aetiology and prevalence has been sparse.6,7 As
defined by the GOLD scientific committee, COPD is
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that is not fully reversible.6,7 Airflow limitation is
usually both progressive and associated with an
abnormal inflammatory response of the lungs to
noxious particles or gases, in particular, tobacco
smoke.6,7 COPD appears to be a multi-component
disease, characterized by airway inflammation,
airway obstruction, structural remodelling of the
airway wall and mucus hypersecretion, as well as
systemic changes, including systemic inflammation,
nutritional abnormalities and weight loss, and
skeletal muscle dysfunction.6–8 Of note, these
components may lead to acute exacerbations of
COPD, defined by increased symptoms and worsen-
ing lung function, which have profound effects on
both quality of life and healthcare costs.9–11
Current pharmacological therapies for the treat-
ment of COPD have limitations, particularly in
relation to reducing the progression of the dis-
ease.1,12 Given the multi-component nature of
COPD, multiple therapies will probably be required
to treat it and one strategy may be to use current
treatment options in combination.12 However, since
chronic inflammation is a critical underlying factor
in the development of COPD, new therapies with a
novel anti-inflammatory mechanism of action may
provide additional benefits. One potential candi-
date is the selective phosphodiesterase (PDE)4
inhibitors, which have proven anti-inflammatory
effects, coupled with an improved therapeutic
ratio versus existing non-selective PDE inhibi-
tors.13,14
In this article, I describe the significant role that
inflammation appears to play in the pathogenesis of
COPD, the impact of PDE4 inhibitors in reducing
inflammation via increased accumulation of the
cyclic nucleotide, adenosine 30,50-cyclic monopho-
sphate (cAMP), and the potential advantages of
second generation, selective PDE4 inhibitors (e.g.
cilomilast and roflumilast) over first generation
compounds (e.g. rolipram) and non-selective PDE
inhibitors (e.g. theophylline) in the treatment of
COPD.
Mechanism of chronic inflammation in
COPD
Although the processes underlying COPD are not yet
fully elucidated, chronic inflammation appears to
have an important part (Fig. 1). Of note, sub-
stantial differences are apparent compared with
the inflammatory mechanisms involved in the
development of asthma.12,15 Inflammation plus
structural alterations occurring in the small airways
and lung parenchyma, such as fibrosis, smooth
muscle hypertrophy, goblet cell metaplasia and
lumen occlusion by mucus plugging, are major
contributors to the airflow limitation and acceler-
ated decline of forced expiratory volume in one
second (FEV1) observed in COPD.
15,16 Key inflam-
matory cells implicated in COPD pathophysiology
include neutrophils, macrophages and T cells
(predominantly, CD8þ cells).15,16 In addition,
structural cells, e.g. epithelial cells, fibroblasts
and smooth muscle cells, participate via the
release of a variety of mediators, including
cytokines, chemokines and growth factors, such
as leukotriene B4 (LTB4), interleukin (IL)-8 and
tumour necrosis factor (TNF)-a.6,15,16 It has been
proposed that an imbalance between pro- and anti-
inflammatory cytokines may be involved in the
process of neutrophil accumulation, for example,
IL-8 and TNF-a levels are elevated.16 Together,
airway inflammation and remodelling may also lead
to degradation of the lung parenchyma, most likely
mediated through release of proteolytic enzymes
(such as elastase) from inflammatory cells, result-
ing in emphysema.15,16
Degradation of cAMP by the PDEs (in particular,
PDE4) has been hypothesized to be an important
target to reduce the chronic inflammation, that is,
characteristic of COPD. cAMP is a secondary
messenger involved in signal transduction in a
range of cellular processes, including cellular
growth, sensory signalling, neuroplasty and tran-
scription, as well as inflammation.17 Increases in
cAMP levels result in activation of protein kinase A
(PKA) and enhanced protein phosphorylation,
which in turn leads to inhibitory effects on many
inflammatory and immunomodulatory cells.18
These effects include relaxation of airway smooth
muscle, inhibition of chemotaxis, abnormal release
of inflammatory and cytotoxic mediators and
inhibition of proliferation (as well as infiltration)
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Figure 1 Pathogenesis of COPD, IL-8¼ interleukin-8;
LTB4¼ leukotriene B4; TNF-a¼ tumor necrosis factor-a;
IL-10¼ interleukin-10.
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of inflammatory cells.18,19 Intracellular cAMP levels
are regulated by a number of factors, notably by
the PDEs, which catalyse the degradation of
cAMP.17,18 The PDE superfamily consists of at least
11 isozymes, which vary in their distribution among
different tissues/cell types (Fig. 2).19 The predo-
minant isoenzyme in inflammatory and immunomo-
dulatory cells, PDE4, is expressed in many airway
cells involved in the pathogenesis of COPD, includ-
ing neutrophils, macrophages, T cells and endothe-
lial cells (Table 1).18,19 Hence, since PDE4 inhibition
has the potential to produce significant anti-
inflammatory and disease modifying effects by
increasing accumulation of intracellular cAMP,
PDE4 represents a promising molecular target for
the treatment of COPD.14,20–22
PDE4 inhibitorsFmechanism of action
and benefits over theophylline
In spite of their collective effects on PDE inhibition,
there are a number of important differences
between the mechanisms of action of the non-
selective PDE inhibitor, theophylline, and that of
the selective PDE4 inhibitors (Table 2). Further-
more, second generation compounds have signifi-
cant benefits over the first generation PDE4
inhibitors.
Theophylline
Theophylline, a broad spectrum PDE inhibitor, has
been used to treat pulmonary diseases for over a
century. It has established anti-inflammatory and
immunomodulatory effects, possibly mediated by
inhibition of the degradation of cAMP,23–25 although
PDE inhibition may be negligible at therapeutically
relevant concentrations of theophylline (see be-
low).26 However, although the mechanism of action
of theophylline remains unclear, it appears to have
a range of distinct features compared with the
selective PDE4 inhibitors.26
Firstly, theophylline is a weak and non-selective
PDE inhibitor, which indiscriminately inhibits all
PDEs in all tissues and organs of the body, including
the gastrointestinal, cardiovascular and central
nervous systems (Fig. 2).18,26,27 There is no evi-
dence that theophylline has any selectivity
for a particular isoenzyme, such as PDE4.26 Non-
selective PDE inhibition leads to elevation of
cGMP, as well as cAMP, levels, resulting in the
activation of both cAMP- and cGMP-dependent
kinases (PKA and protein kinase G), linked
with an increase in adverse events.26,28 Secondly,
theophylline is a potent adenosine receptor an-
tagonist at concentrations within the therapeutic
range.26,29 This effect may be responsible for
several of the serious side effects of theophylline,
including seizures and cardiac arrhythmias.26 To-
gether, non-selective PDE inhibition and adenosine
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Figure 2 Tissue distribution of human PDEs, adapted with permission from Essayan.19
Table 1 cAMP-metabolizing enzymes in human
immune and inflammatory cells.
Cell cAMP PDEs
Basophils 3 and 4
B cells Unknown
Eosinophils 4
Macrophages 3 and 4
Mast cells 3 and 4
Monocytes 4
Neutrophils 4
T cells 3, 4 and 7
Adapted with permission from Torphy.18
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Table 2 Comparison of cilomilast and theophylline.
Theophylline Cilomilast
Mechanism of action
Non-selective PDE inhibitor, leading to
m cAMP and m cGMP26
Potent and selective PDE4 inhibitor,
leading to m cAMP only
PDE inhibition may be negligible at
therapeutic concentrations26
PDE4 inhibition at therapeutic
concentrations
Adenosine receptor antagonist26 No action on adenosine receptors
Pharmacokinetics
General Non-linear pharmacokinetics, with
significant inter-subject variability,
including effects of smoking, age,
concomitant medicationsFnecessitates
plasma monitoring42,43,47,50,66
Linear pharmacokinetics, unaffected by
smokingFno requirement for plasma
monitoring3,49,53
Convenient oral tablet, dosed twice-daily
Absorption Variable, depends on formulation67 Rapid (TmaxB1–2 h), slower with
food3,49,53
Bioavailability Variable, depends on formulation67 100%; unaffected by food or co-
administration of antacids3,49,53
Half life B7–9 h47 B7–8 h3,49,53
Volume of
distribution
0.5 l/kg body weight; plasma protein
binding B56%50
Low; plasma protein bindingB99.5%3,49,53
Total plasma
clearance
B0.4 l/h/kg; affected by genetic factors,
environmental agents (including tobacco
smoke), pathological conditions and
concomitant drug treatments that affect
hepatic metabolism47
Low (o 2 l/h)3,53
Metabolism B90% metabolized in liver by the CYP
pathway, mainly by CYP1A2 (CYP2E1/
CYP3A3/4 also contribute)47,50
Subject to negligible first pass hepatic
metabolism, extensively metabolized
(main routes¼ decyclopentylation, acyl
glucuronidation and 3–hydroxylation of
the cyclopentyl ring)3
Essentially no inhibition of CYP isoenzymes
(CYP2C8?)3
Drug interactions Potential drug interactions include
propafenone, mexiletine, enoxacin,





Low potential for drug interactions, and
can be taken safely with many other
medications that are commonly prescribed
to patients with COPD3
Excretion Only B10% excreted via the kidneys in
unchanged form47,50
Mainly excreted in urine (B90%) and
faeces (6–7%), unchanged cilomilast
accounts for less than 1% of administered
dose3
Special populations Dose adjustment may be required in
smokers, the elderly, those with liver
disease or patients taking concomitant
medications; contraindicated in heart
disease, seizure disorders and
gastroesophageal reflux46,47,50–52,54
No dose adjustment required in smokers or
the elderly3,49; use with caution in mild-
to-moderate hepatic impairment and
severe renal impairment; contraindicated
in severe hepatic impairment
Clinical efficacy
Modest dose–response effect42 Dose dependent improvements in lung
function, with FEV1 improvements
maintained over 6 months55,57
Only effective in subset of patients42 Effective in smokers and non-smokers58
Slow onset of effect42 Decreases rate of exacerbations and
improves quality of life3,55,56
Demonstrated anti-inflammatory effects




Serious cardiovascular and central nervous
system side effects45
No cardiovascular/central nervous system
side effects
10–15% of patients experience
gastrointestinal side effects, insomnia or
other minor side effects42
Generally well toleratedFmild-to-
moderate GI effects may occur, but these
are self-limiting and easily managed55
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antagonism are likely to be responsible for many or
all of the toxic side effects associated with
theophylline use.26,27,29
Of note, the degree of PDE inhibition may be
negligible at concentrations of theophylline that
are therapeutically relevant.26 For example, in
human lung extracts, theophylline at therapeutic
concentrations has been shown to inhibit total PDE
activity by only 5–10%.26 There is growing evidence
that theophylline works via other mechanisms than
PDE inhibition and recent findings from asthma
studies have indicated that its mode of action
involves modification of histone acetylation, lead-
ing to changes in gene expression.26,30 However,
theophylline’s precise mechanism of action in COPD
remains unknown.
First generation PDE4 inhibitors (e.g.
rolipram)
Preclinical studies with first generation compounds
such as rolipram that selectively inhibit PDE4 have
demonstrated impressive activity in animal models
of pulmonary inflammation.18,27,31 However, these
agents were found to be associated with significant
classFassociated side effects, such as nausea and
vomiting, and gastric acid secretion, caused by
inhibition of PDE4 in the central nervous system and
parietal glands, respectively.14 These findings
necessitated the development of PDE4 inhibitors
with an improved therapeutic ratio.
Second generation PDE4 inhibitors (e.g.
cilomilast and roflumilast)
The most clinically advanced selective PDE4
inhibitors (cilomilast and roflumilast) have a super-
ior side effect profile compared with theophylline
and first generation compounds.14 These com-
pounds were designed with the knowledge that
PDE4 exists in two distinct conformations, high
affinity rolipram-binding PDE4 (HPDE4; which pre-
dominates in the central nervous system and
parietal glands) and low affinity rolipram-binding
PDE4 (LPDE4; which predominates in immunocom-
petent cells).14 Unlike rolipram, which targets
HPDE4, second generation compounds (such as
cilomilast) primarily target LPDE4 (Fig. 2), resulting
in an improved therapeutic index.14
Selective inhibition of PDE4 increases cAMP
content in many inflammatory and immunomodu-
latory cells, leading to suppression of numerous
aspects of the inflammatory response, as well as
effects on smooth muscle and pulmonary nerves
(Fig. 3). Indeed, second generation PDE4 inhibitors
have demonstrated pronounced anti-inflammatory
effects in various animal models.18,21,22,32–34 Cilo-
milast/roflumilast inhibit the activity of cells that
have been implicated in the pathogenesis of COPD,
e.g. neutrophils,35,36 monocytes,35 macrophages,35
CD4T cells,35 epithelial cells37 and fibroblasts.38,39
Additionally, cilomilast has recently been shown to
decrease levels of CD8þT cells and CD68þmacro-
phages, thus demonstrating its potent anti-inflam-
matory effects.40 Other effects of cilomilast and
roflumilast include reduced chemotaxis, activation,
degranulation and adherence of inflammatory
cells, impact on key mechanisms involved in airway
remodelling and modulation of the release of
inflammatory mediators, such as TNF-a, IL-8, and
GM-CSF.32,34,37–39,41 Significantly, cilomilast retains
the anti-inflammatory actions of rolipram, but is




The pharmacokinetics of the selective PDE4 in-
hibitors are markedly different from those of
theophylline (for a detailed comparison of cilomi-
last versus theophylline, see Table 2). This has a
number of implications in terms of the relative ease
of use of these compounds and the extent of plasma
monitoring required.
Theophylline is a difficult drug to use clinically,
owing to significant inter- and intra-subject varia-
bility in pharmacokinetics.42 It has a narrow
therapeutic margin and requires careful titration,
with routine plasma monitoring, in order to reduce
the risk of related adverse events.42,43 For exam-
ple, potentially dangerous complications can
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Figure 3 Mechanisms of PED4 inhibition in COPD,
adapted with permission from Torphy et al.14
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occur with theophylline when plasma levels rise
above 20 mg/ml, e.g. cardiovascular events, includ-
ing arrythmias44 and central nervous system
events, including convulsions.45 In particular, care-
ful plasma monitoring and dose adjustments are
required in smokers and elderly patients.3,46,47 This
has important consequences for the cost of
therapy. While theophylline is generally considered
to be a low price medication, it has been estimated
that total annual costs, including hospital admis-
sions for toxic events and plasma monitoring, are
higher for patients taking theophylline compared
with other bronchodilators.42 In contrast to asth-
ma, where recent evidence suggests that many of
the beneficial effects of theophylline can be
observed at low doses, there is evidence of a
modest dose–response effect in patients with
COPD,42,48 which is particularly relevant to the
problems associated with its narrow therapeutic
margin.
In contrast, the pharmacokinetics of cilomilast
are unaffected by smoking.3,49 In the elderly,
although there may be a small reduction in
cilomilast clearance, this is not considered to be
of clinical concern and does not necessitate dose
adjustment.49
Use of theophylline is also complicated by the
range of potential drug interactions that may occur.
Theophylline is metabolized by the cytochrome
P450 (CYP) pathway, predominantly by CYP1A2,
with a smaller contribution from CYP2E1 and
CYP3A4. This leads to numerous potential drug
interactions, including B2 agonists, cimetidine,
ciprofloxacin, lithium, prednisolone, oral contra-
ceptives, rifampicin, digoxin, warfarin, propafe-
none, mexiletine, enoxacin, propranolol,
erythromycin, phenytoin, carbamazepine, pheno-
barbital, isoproterenol and tobacco smoke.47,50–52
In contrast, cilomilast has a superior drug interac-
tions profile compared with theophylline. Cilomi-
last does not inhibit any important CYP isoenzymes
and therefore has a low potential for drug interac-
tions.3 Although CYP2C8 has been implicated in
cilomilast metabolism, this enzyme has few other
substrates or inhibitors.3 Importantly, there is no
evidence of drug interactions between cilomilast
and warfarin, theophylline, digoxin, aluminium/
magnesium hydroxide antacid, prednisolone or
salbutamol.3,53 Furthermore, several pathological
conditions affect theophylline metabolism and
clearance, including congestive heart failure, cir-
rhosis, pulmonary oedema, cor pulmonale/
COPD, obesity and systemic viral infection.50
Theophylline is contraindicated in patients with
heart disease, seizure disorders and gastroesopha-
geal reflux.54
Clinical dataFbenefits of PDE4 inhibitors
over theophylline
Efficacy
Theophylline is the most frequently prescribed oral
bronchodilator for the chronic maintenance treat-
ment of chronic obstructive airway disorders.42
However, there is some debate as to the role of
theophylline in the treatment of COPD compared
with newer agents (Table 2). For example, only a
modest dose–response effect has been demon-
strated, with just small changes in FEV1, forced
vital capacity (FVC) and peak expiratory flow rate
(PEFR) observed over the range of doses that
induce theophylline concentrations of 5–10 mg/ml,
10–15 mg/ml and 15–20 mg/ml.42 It has been sug-
gested that high doses of theophylline may be
needed to induce a significant increase in FEV1, but
even when this is achieved, its bronchodilator
action is often limited.42 In fact, the slow onset
of action of theophylline coupled with difficulties in
achieving stable plasma levels mean that most
effects do not occur until 2–6 weeks.42 Of further
concern, its effectiveness may be restricted to a
subset of patients with COPD and it may be difficult
to predict responders.42 Additionally, withdrawal of
theophylline should be carried out with caution
because of possible deterioration in lung func-
tion.42 Given these efficacy concerns, together
with its toxicity issues, use of theophylline as
monotherapy in COPD should be restricted to the
rare cases where patients cannot adequately
administer inhalers.42 Indeed, GOLD guidelines
recommend that inhaled bronchodilators are pre-
ferable to theophylline, when available.6,7
In contrast, the selective PDE4 inhibitors have
demonstrated encouraging efficacy to date. Ac-
cording to published data, the most advanced PDE4
inhibitor in clinical development is cilomilast. This
compound has been shown to improve both
pulmonary function and symptoms of COPD in 424
patients with moderate-to-severe disease, produ-
cing significant improvements in FEV1, FVC and
PEFR versus placebo over 6 weeks.55 In this study,
cilomilast use was also associated with improve-
ments in rescue bronchodilator use, exertional
dyspnea, and resting and post-exercise arterial
oxygen saturation (SaO2).
14,55 In addition, consis-
tent improvements in patient quality of life
approaching that defined as clinically relevant
were observed compared with placebo.3,55 Further-
more, cilomilast significantly reduces the risk of
exacerbations, both self-managed and those
requiring physician intervention or hospitalization,
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and provides sustained improvements in lung
function over 6 months in patients with mild-to-
moderate disease.56,57 Importantly, the improve-
ments in lung function observed with cilomilast are
independent of smoking status.58 More recently,
the anti-inflammatory effects of cilomilast obs-
erved in preclinical studies have been confirmed in
a small, randomized, placebo-controlled trial of 59
patients with COPD.40 After 12 weeks of cilomilast
therapy, bronchial biopsies taken from treated
patients indicated that cilomilast significantly
reduces levels of inflammatory markers, i.e.
CD8þT cells and CD68þmacrophages.40 These
results represent the first demonstration by any
agent of a reduction in airway tissue inflammatory
cells characteristic of COPD.40
Roflumilast has also shown encouraging efficacy
in patients with COPD, with significant improve-
ments observed in FEV1 and PEFR versus baseline,
59
although only limited published data are available
at present.
Safety and tolerability
A major benefit of cilomilast and roflumilast is their
superior safety and tolerability profile versus
theophylline and the first generation PDE4 inhibi-
tors (Table 2).
Theophylline is associated with serious cardio-
vascular and central nervous system side effects,
even at therapeutic doses.42,45,60 These effects are
generally attributed to non-selective inhibition of
PDEs, as well as concomitant adenosine receptor
antagonism,26,27,29 and include tachycardia and
serious arrhythmias, focal and generalized sei-
zures, and coma.45,60 Acute theophylline overdose
is associated with metabolic and electrolyte
abnormalities, including hypokalaemia, hypergly-
caemia, leukocytosis and elevated serum catecho-
lamine levels.45 Moreover, approximately 10–15% of
patients receiving theophylline will experience
gastrointestinal adverse events, insomnia or other
minor side effects.42 Although side effects can be
reduced by ensuring that theophylline plasma
concentrations do not enter the high therapeutic
range, many physicians do not provide adequate
monitoring of theophylline levels before or during
long-term treatment.42 Despite the low price of
theophylline, the overall cost may be greater than
other bronchodilators owing to its toxic effects,
including hospital admissions and blood level
monitoring.42
When the first generation PDE4 inhibitors were
developed, it was envisaged that these compounds
would have fewer side effects than theophylline,
due to their selectivity for PDE4.14 However, these
agents were associated with a number of adverse
events, including nausea, vomiting and gastric acid
secretion, which limit their clinical use.14
In contrast, second generation PDE4 inhibitors
have an improved therapeutic ratio.14 Cilomilast
has proven safe and well tolerated at doses of up to
15mg in both short- and long-term dosing trials,
with a low incidence of adverse events.3,55
Although cilomilast does cause some gastrointest-
inal adverse events, most notably, nausea, this is
generally mild-to-moderate and self-limiting.55
Cilomilast can also be taken safely with many other
medications that are commonly prescribed to
patients with COPD. Similarly, preliminary findings
indicate that roflumilast is also safe and well
tolerated in patients with COPD,61–65 although only
limited published data are available at present.
Conclusions
COPD is a serious chronic condition, which is
increasingly being recognized as having a significant
inflammatory component. New treatments are
required that reduce inflammation and delay
disease progression, and inhibition of PDE4 repre-
sents a promising mechanism to treat COPD, given
the resulting effects on inflammation and asso-
ciated underlying disease processes. Although our
preconceptions of theophylline as an agent with
PDE inhibitory activity draws us to compare
theophylline with specific second generation PDE4
inhibitors, this may not be consistent with the
current state of our scientific understanding.
Theophylline and first generation PDE4 inhibitors
(e.g. rolipram) are limited by poor efficacy and
unfavourable safety and tolerability, resulting from
their lack of selectivity. In contrast, second gen-
eration PDE4 inhibitors (e.g. cilomilast and roflu-
milast) are more selective and preliminary efficacy
and safety/tolerability findings from large clinical
trials, and using newer methods of measuring
efficacy, are promising. These agents are likely to
be of benefit in the treatment of COPD, particularly
in combination with other agents, due to their
novel mechanism of action and anti-inflammatory
effects, and without the hazards and inconvenience
of older agents posed to the prescribing physician.
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